Mizuho Cuts Embecta (NASDAQ:EMBC) Price Target to $5.00

Embecta (NASDAQ:EMBC) had its target price lowered by Mizuho from $12.00 to $5.00 in a research report released on Wednesday morning, Marketbeat reports. The firm currently has a neutral rating on the stock.

Several other analysts have also commented on EMBC. Weiss Ratings restated a “hold (c-)” rating on shares of Embecta in a research report on Wednesday, January 21st. Wall Street Zen upgraded shares of Embecta from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Finally, BTIG Research lowered shares of Embecta from a “buy” rating to a “neutral” rating in a research report on Tuesday. Three investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus price target of $15.00.

Embecta Stock Performance

EMBC stock opened at $3.64 on Wednesday. The firm has a market cap of $215.96 million, a PE ratio of 1.92 and a beta of 1.09. The firm’s fifty day moving average is $8.85 and its 200 day moving average is $11.06. Embecta has a one year low of $3.45 and a one year high of $15.55.

Embecta (NASDAQ:EMBC) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.27 EPS for the quarter, missing the consensus estimate of $0.42 by ($0.15). The firm had revenue of $221.80 million for the quarter, compared to analyst estimates of $235.67 million. Embecta had a net margin of 10.73% and a negative return on equity of 23.96%. The firm’s quarterly revenue was down 14.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.70 EPS. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. Research analysts predict that Embecta will post 1.65 earnings per share for the current fiscal year.

Embecta Cuts Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, June 15th. Stockholders of record on Thursday, May 28th will be given a $0.01 dividend. The ex-dividend date is Thursday, May 28th. This represents a $0.04 annualized dividend and a dividend yield of 1.1%. Embecta’s dividend payout ratio (DPR) is 31.58%.

Institutional Trading of Embecta

Several institutional investors have recently modified their holdings of EMBC. Larson Financial Group LLC grew its position in shares of Embecta by 368.6% in the third quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock valued at $28,000 after purchasing an additional 1,574 shares during the period. Tower Research Capital LLC TRC grew its position in shares of Embecta by 542.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock valued at $71,000 after purchasing an additional 6,224 shares during the period. Wexford Capital LP acquired a new stake in shares of Embecta in the third quarter valued at about $94,000. Humankind Investments LLC acquired a new stake in shares of Embecta in the second quarter valued at about $111,000. Finally, iSAM Funds UK Ltd acquired a new stake in shares of Embecta in the third quarter valued at about $115,000. Institutional investors and hedge funds own 93.83% of the company’s stock.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.